LM-350 / Sino Biopharm, LaNova Medicines Limited - LARVOL DELTA

A Study of LM-350 in Subjects With Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=80 | Recruiting | Sponsor: LaNova Medicines Limited | Not yet recruiting ➔ Recruiting | N=55 ➔ 80

Enrollment change • Enrollment open • First-in-human • Solid Tumor

Sino Biopharmaceutical Says LM-350 CDH17 Antibody-Drug Conjugate Receives Clinical Trial Approval From China's NMPA (TradingView)

New trial • Oncology

COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE I CLINICAL TRIAL OF LM-350 “CDH17 ADC” IN AUSTRALIA (HKEXnews) - "This clinical study is an open-label, dose escalation and dose expansion Phase I/II clinical study evaluating the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LM-350 in patients suffering advanced solid tumors."

Enrollment status • Solid Tumor

A Study of LM-350 in Subjects With Advanced Solid Tumours (clinicaltrials.gov) - P1/2 | N=55 | Not yet recruiting | Sponsor: LaNova Medicines Limited

New P1/2 trial • Solid Tumor

IND APPROVAL FOR LM-350 “CDH17 ADC” FROM THE US FDA (HKEXnews) - "The board of directors (the 'Board') of Sino Biopharmaceutical Limited (the 'Company', together with its subsidiaries, the 'Group') announces that LM-350 'CDH17 ADC', an innovative drug independently developed by LaNova Medicines Limited ('LaNova Medicines', a wholly-owned subsidiary of the Group) has been granted the Investigational New Drug (IND) approval from the United States Food and Drug Administration ('FDA')."

IND • Solid Tumor

Preclinical evaluation of LM-350: An innovative anti-CDH17 antibody drug conjugate for gastrointestinal cancer therapy (AACR 2025) - "The novel ADC LM-350 targeting CDH17 exhibited potent anti-tumor activity in vitro and in CRC and GC xenograft models. LM-350 demonstrated high therapeutic potential in CDH17-positive gastrointestinal cancers, particularly in CRC and GC."

Preclinical • Gastrointestinal Cancer • Oncology • Pancreatic Cancer • Solid Tumor • CDH17